Diagnostics for multiple myeloma
1Clinical Laboratory Department, Yokohama City University Hospital.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 1, 2016
Summary
The International Myeloma Working Group (IMWG) updated multiple myeloma (MM) diagnostic criteria in 2014. These changes enable earlier diagnosis and treatment for patients with high-risk smoldering MM.
Area of Science:
- Hematology
- Oncology
- Clinical Diagnostics
Background:
- Multiple myeloma (MM) diagnosis historically relied on International Myeloma Working Group (IMWG) criteria established in 2003.
- The 2014 IMWG update introduced specific biomarkers to refine MM diagnosis.
Purpose of the Study:
- To review the updated IMWG diagnostic criteria for multiple myeloma (MM).
- To discuss the evaluation of patients newly diagnosed with MM.
Main Methods:
- The review focuses on the three key biomarkers added in the 2014 IMWG criteria update.
- These biomarkers include clonal bone marrow plasma cell percentage, serum free light chain ratio, and MRI findings of focal lesions.
- Diagnosis is considered in conjunction with CRAB features (hypercalcemia, renal failure, anemia, bone lesions).
Main Results:
- The updated criteria allow for early diagnosis of MM, particularly in patients with ultra-high-risk smoldering MM.
- Timely initiation of anti-MM treatment is facilitated by these refined diagnostic guidelines.
Conclusions:
- The 2014 IMWG criteria enhance the accuracy of MM diagnosis.
- Early identification of MM, especially smoldering forms, is crucial for effective patient management and treatment initiation.
